

# Selectivity of dopamine D<sub>1</sub> and D<sub>2</sub> receptor agonists

## A combined computational approach

**MARCUS MALO**

Institutionen för kemi och molekylärbiologi  
Naturvetenskapliga fakulteten



GÖTEBORGS UNIVERSITET

Akademisk avhandling för filosofie doktorsexamen i kemi, inriktning  
läkemedelskemi, som med tillstånd från Naturvetenskapliga fakulteten kommer att  
offentligt försvaras fredagen den 16 november, 2012, kl. 9.00 i KA-salen,  
Institutionen för kemi och molekylärbiologi, Kemigården 4, Göteborg.

ISBN: 978-91-628-8572-4

## Abstract

Dopamine (DA) is an endogenous neurotransmitter acting in the central nervous system. DA plays a key role in many vital brain functions such as behavior, cognition, motor activity, learning, and reward. Dopamine receptors belong to the rhodopsin like family of G-protein coupled receptors (GPCRs). There are five subtypes of DA receptors (D<sub>1</sub>-D<sub>5</sub>), which are further divided into two main families based on sequence similarities and their coupling to intracellular signaling (D<sub>1</sub>- and D<sub>2</sub>-like receptors). Dopamine agonists mimic the effects of the natural neurotransmitter and it has been found that selective dopamine D<sub>2</sub> or D<sub>1</sub> and mixed D<sub>1</sub>/D<sub>2</sub> agonists are useful in the treatment of Parkinson disease. As D<sub>2</sub> (but not D<sub>1</sub>) agonists have shown undesirable dyskinetic effects it is of highest interest to understand the reasons behind D<sub>1</sub>/D<sub>2</sub> agonist selectivity.

This thesis is focused on the identification of structural features that determine the selectivity of D<sub>1</sub> and D<sub>2</sub> receptor agonists for their respective receptors. Selective pharmacophore models were developed for both receptors. The models were built by using projected pharmacophoric features that represent the main agonist interaction sites in the receptor, and excluded volumes where no heavy atoms are permitted. The sets of D<sub>1</sub> and D<sub>2</sub> ligands used for modeling were carefully selected from published sources and consist of structurally diverse, conformationally rigid full agonists as active ligands together with structurally related inactives.

3D receptor models in their agonist bound state were also generated for dopamine D<sub>1</sub> and D<sub>2</sub>, in order to get improved insight into agonist binding. The constructed D<sub>1</sub> and D<sub>2</sub> agonist pharmacophore models were superimposed into their corresponding receptor model. The arrangement of pharmacophoric features were in agreement with the position of the agonist key interacting amino acids in the binding site, with exception of one hydrogen bond accepting/donating feature in the D<sub>2</sub> model and the positioning of the excluded volumes in both models. Both pharmacophore models were refined to better reflect the shape of the binding pocket and had similar pharmacophore hit rate when screening the test sets of dopamine ligands. Several key factors for D<sub>1</sub>/D<sub>2</sub> agonist selectivity were identified.

In addition, a semi-empirical method to model transmembrane proteins with focus on the ligand binding site has been developed. The method was evaluated by generating a  $\beta_1$ -adrenergic receptor model which had an RMSD of 1.6 Å for all heavy atoms in the binding site relative the crystal structure. A D<sub>2</sub> receptor model with an agonist present was constructed, but this model was unable to discriminate actives from inactives in a docking study.

---

Keywords: dopamine, agonists, GPCRs, pharmacophore modeling, protein structure modeling, agonist selectivity